Bulletin from the extraordinary shareholders' meeting in Enzymatica
14 April 2016 - 10:27PM
Today on 14 April 2016, an
extraordinary shareholders' meeting was held in Enzymatica AB
(publ) ("Enzymatica" or the "Company"). The meeting decided on a
rights issue with pre-emptive right for the
shareholders with expected proceeds of
approximately SEK 60 million before issue costs. In addition the
meeting decided to authorise the board of
directors until the next annual shareholders' meeting to increase
the Company's share capital by a directed share issue of no more
than 17,500,000 new shares. A summary of the
resolutions adopted follows below. All resolutions were adopted
unanimously.
Amendment to the articles of
association
The meeting resolved in accordance with the proposal of the board
of directors to amend the articles of association as follows.
|
Previous wording |
Adopted wording |
§ 4 |
The share capital shall be no less than SEK 500,000 and no
more than SEK 2,000,000. |
The share capital shall be no less than SEK
1,500,000 and no more than SEK 6,000,000. |
§ 5 |
The number of shares in the Company shall not be lower than
12,500,000 and not higher than 50,000,000. |
The number of shares in the Company shall not be lower than
37,500,000 and not higher than 150,000,000. |
Rights issue with pre-emptive
right for the shareholders
The meeting resolved in accordance with the proposal of the board
of directors on a rights issue with expected proceeds of
approximately SEK 60 million before issue costs. Through the rights
issue, the Company's share capital can be increased with a maximum
amount of SEK 1,100,817.12 divided into a maximum of 27,520,428
shares. The main terms and conditions for the rights issue are as
following.
The Company's shareholders shall have pre-emptive
right to subscribe for new shares in proportion to the shares
previously owned. Each previously owned share confers the right to
one (1) subscription right. Five (5) subscription rights entitles
subscription for three (3) new shares. The subscription price to be
paid shall be SEK 2.18 for each new share.
The record date for entitlement to participate in
the rights issue with pre-emptive right shall be 19 April 2016.
Subscription for new shares shall be made during the time period as
from 21 April 2016 - 6 May 2016. Subscription by exercise of
subscription rights shall be made by simultaneous cash payment.
Subscription for new shares without subscription rights shall be
made on a separate subscription list. Payment for new shares
subscribed for without subscription rights shall be made in cash no
later than the third bank day from dispatch of the contract note
setting forth the allotment of shares to the subscriber. The board
of directors shall be entitled to extend the period for
subscription and payment.
Authorisation of the board of
directors to issue new shares
The meeting resolved in accordance with the proposal of the board
of directors to authorise the board of directors until the next
annual shareholders' meeting to, on one or more occasions, resolve
to increase the Company's share capital by issue of no more than
17,500,000 new shares. The board of directors may deviate from the
shareholders' preferential rights. The reason for the board of
directors' authorisation to deviate from the shareholders'
preferential rights is to enable the company's possibilities to
raise new capital and to take advantage of future opportunities to
attract new long-term owners of strategic importance to the
company, as well as to finance the Company's growth strategy. The
authorization also includes the right to decide on payment for the
issued shares in kind, set-off or other conditions as referred in
Chap. 13 Sec. 5 item 6 of the Swedish Companies Act (Sw.
Aktiebolagslagen (2005:551)). At a deviation from the shareholders'
preferential rights, the issue rate shall be determined in
accordance with market conditions.
For
more information, please contact:
Fredrik Lindberg, CEO Enzymatica AB
Tel: +46 708-86 53 70 | E-post: fredrik.lindberg@enzymatica.com
About Enzymatica AB
Enzymatica is a life science company who develops and sells medical
device products against infectious-related diseases. Over a short
period the company has developed a unique oral spray for colds,
ColdZyme®, and launched it on six markets. The product has become
one of the leading articles for colds in Swedish pharmacies.
Enzymatica's strategy is to continue growing by strengthening its
position in existing markets and to expand to more geographical
markets through well-established partners. The company is
headquartered in Lund, Sweden and is listed on Nasdaq First North.
For more information, please visit
www.enzymatica.com.
Enzymatica's certified advisor is Erik Penser
Bankaktiebolag.
Press release (PDF)
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Enzymatica AB via Globenewswire
HUG#2003638
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jun 2024 to Jul 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jul 2023 to Jul 2024